Suppr超能文献

甘氨酰-β-鼠胆酸调节胆汁酸代谢以减轻基因敲除小鼠的肝胆损伤。

Gly-βMCA modulates bile acid metabolism to reduce hepatobiliary injury in KO mice.

作者信息

Hasan Mohammad Nazmul, Wang Huaiwen, Luo Wenyi, Du Yanhong, Li Tiangang

机构信息

Harold Hamm Diabetes Center, Department of Biochemistry and Physiology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.

Laboratory for Molecular Biology and Cytometry Research, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.

出版信息

Am J Physiol Gastrointest Liver Physiol. 2025 Jul 1;329(1):G45-G57. doi: 10.1152/ajpgi.00044.2025. Epub 2025 May 26.

Abstract

Cholestasis results from impaired bile flow that causes accumulation of hepatic bile acid and injury. Alleviating bile acid hepatobiliary toxicity is a major therapeutic goal in cholestasis. Our recent study revealed a potent anticholestasis effect of glycine-conjugated β-muricholic acid (Gly-βMCA) in knockout (KO) mice with humanized hydrophobic bile acid composition. To better understand the mechanisms and human relevance of the therapeutic benefits of Gly-βMCA, we investigated the effects of Gly-βMCA on bile acid metabolism and biliary injury in KO mice, a cholestasis model with a hydrophilic murine bile acid composition. Gly-βMCA significantly reduced serum alkaline phosphatase (ALP), ductular reaction, and liver cytokine expression in female mice but offered little benefits in male mice. Consistently, Gly-βMCA reduced hepatic bile acids and total bile acid pool size in female but not male mice, due to its ability to promote fecal bile acid excretion. However, the endogenous taurine-conjugated muricholic acid (T-MCA) limited the ability of Gly-βMCA to further enrich the bile acid pool with Gly-βMCA-derived T-βMCA to reduce bile acid hydrophobicity. Overall, Gly-βMCA showed diminished therapeutic efficacy in KO mice than KO mice, which may be due to differences in bile acid hydrophobicity and disease etiology in the two cholestasis models. These findings suggest that the benefits of Gly-βMCA are mediated by its unique pharmacokinetics, which allows for simultaneous reduction of bile acid pool size and hydrophobicity. Gly-βMCA may be a promising therapy for treating human cholestasis, despite its reduced efficacy in improving the toxicity profile of murine bile acid pool. Gly-βMCA decreases liver injury in female but not male KO mice. Gly-βMCA blocks bile acid absorption to reduce bile acid pool in female KO mice. Gly-βMCA reduces bile acid hydrophobicity by causing T-βMCA enrichment in bile, but this therapeutic benefit was partially masked by a murine bile acid composition due to abundantly synthesized T-MCA in KO mice. Gly-βMCA alleviates bile acid hepatobiliary toxicity by reducing both bile acid pool size and hydrophobicity.

摘要

胆汁淤积是由胆汁流动受损导致肝胆汁酸积聚和损伤引起的。减轻胆汁酸的肝胆毒性是胆汁淤积治疗的主要目标。我们最近的研究揭示了甘氨酸结合型β-鼠胆酸(Gly-βMCA)在具有人源化疏水胆汁酸组成的基因敲除(KO)小鼠中具有强大的抗胆汁淤积作用。为了更好地理解Gly-βMCA治疗益处的机制及其与人类的相关性,我们研究了Gly-βMCA对具有亲水性鼠胆汁酸组成的KO小鼠胆汁酸代谢和胆管损伤的影响。Gly-βMCA显著降低了雌性小鼠的血清碱性磷酸酶(ALP)、小胆管反应和肝脏细胞因子表达,但对雄性小鼠益处不大。一致的是,由于Gly-βMCA促进粪便胆汁酸排泄的能力,它减少了雌性而非雄性小鼠的肝脏胆汁酸和总胆汁酸池大小。然而,内源性牛磺酸结合型鼠胆酸(T-MCA)限制了Gly-βMCA通过Gly-βMCA衍生的T-βMCA进一步丰富胆汁酸池以降低胆汁酸疏水性的能力。总体而言,Gly-βMCA在KO小鼠中的治疗效果比在KO小鼠中减弱,这可能是由于两种胆汁淤积模型中胆汁酸疏水性和疾病病因的差异。这些发现表明,Gly-βMCA的益处是由其独特的药代动力学介导 的,这使得它能够同时降低胆汁酸池大小和疏水性。尽管Gly-βMCA在改善鼠胆汁酸池毒性方面的功效降低,但它可能是治疗人类胆汁淤积的一种有前途的疗法。Gly-βMCA可减轻雌性而非雄性KO小鼠的肝损伤。Gly-βMCA通过阻止胆汁酸吸收来减少雌性KO小鼠的胆汁酸池。Gly-βMCA通过导致胆汁中T-βMCA富集来降低胆汁酸疏水性,但由于KO小鼠中大量合成的T-MCA,这种治疗益处被鼠胆汁酸组成部分掩盖。Gly-βMCA通过降低胆汁酸池大小和疏水性来减轻胆汁酸的肝胆毒性。

相似文献

1
甘氨酰-β-鼠胆酸调节胆汁酸代谢以减轻基因敲除小鼠的肝胆损伤。
Am J Physiol Gastrointest Liver Physiol. 2025 Jul 1;329(1):G45-G57. doi: 10.1152/ajpgi.00044.2025. Epub 2025 May 26.
3
来自美洲 Silphium perfoliatum L. 的咖啡酰奎宁酸通过调节胆汁酸的肠肝循环对胆汁淤积小鼠显示出肝保护作用。
J Ethnopharmacol. 2025 Jan 30;337(Pt 2):118870. doi: 10.1016/j.jep.2024.118870. Epub 2024 Sep 30.
5
转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
在具有人源化胆汁酸组成的基因敲除小鼠中,肝胆汁酸蓄积与胆汁淤积性肝损伤和治疗反应相关。
Am J Physiol Gastrointest Liver Physiol. 2024 Dec 1;327(6):G789-G809. doi: 10.1152/ajpgi.00129.2024. Epub 2024 Oct 1.
7
肝脏GDP-岩藻糖转运蛋白SLC35C1通过诱导CEACAM1 N153岩藻糖基化减轻胆汁淤积性肝损伤和炎症。
Hepatology. 2025 Mar 1;81(3):774-790. doi: 10.1097/HEP.0000000000001003. Epub 2024 Jul 10.
9
系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
10
联合 ASBT 抑制剂和 FGF15 治疗可提高 Cyp2c70 KO 雌性小鼠而非雄性小鼠胆管病的治疗效果。
J Lipid Res. 2023 Mar;64(3):100340. doi: 10.1016/j.jlr.2023.100340. Epub 2023 Feb 3.

本文引用的文献

2
胆汁酸在肝脏生理和疾病中对细胞应激反应的调节作用
eGastroenterology. 2024 Apr;2(2). doi: 10.1136/egastro-2024-100074. Epub 2024 May 31.
3
胆汁酸信号在代谢和炎症性疾病及药物研发中的作用
Pharmacol Rev. 2024 Oct 16;76(6):1221-1253. doi: 10.1124/pharmrev.124.000978.
4
38例进行性家族性肝内胆汁淤积症3型患者的预后:基因型及对熊去氧胆酸治疗反应的影响
JHEP Rep. 2023 Jul 13;5(10):100844. doi: 10.1016/j.jhepr.2023.100844. eCollection 2023 Oct.
6
联合 ASBT 抑制剂和 FGF15 治疗可提高 Cyp2c70 KO 雌性小鼠而非雄性小鼠胆管病的治疗效果。
J Lipid Res. 2023 Mar;64(3):100340. doi: 10.1016/j.jlr.2023.100340. Epub 2023 Feb 3.
7
Cyp2c70 KO 小鼠回肠胆汁酸转运蛋白抑制可改善胆汁淤积性肝损伤。
J Lipid Res. 2022 Sep;63(9):100261. doi: 10.1016/j.jlr.2022.100261. Epub 2022 Aug 5.
8
联合 ASBT 抑制剂和 FGF15 治疗可改善实验性非酒精性脂肪性肝炎的治疗效果。
Cell Mol Gastroenterol Hepatol. 2021;12(3):1001-1019. doi: 10.1016/j.jcmgh.2021.04.013. Epub 2021 May 7.
9
Cyp2c70 缺陷型小鼠的胆管病和胆汁纤维化可被熊去氧胆酸完全逆转。
Cell Mol Gastroenterol Hepatol. 2021;11(4):1045-1069. doi: 10.1016/j.jcmgh.2020.12.004. Epub 2020 Dec 10.
10
调控具有疏水性胆汁酸组成的小鼠模型中的胆汁酸代谢。
J Lipid Res. 2020 Jan;61(1):54-69. doi: 10.1194/jlr.RA119000395. Epub 2019 Oct 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验